Corrections
Correction to Lancet Oncol 2011; 12: 625 Baan R, Grosse Y, Lauby-Secretan B, et al, on behalf of the WHO International Agency for Research on Cancer Monograph Working Group. Carcinogenicity of radiofrequency electromagnetic fields. Lancet Oncol 2011; 12: 624–26—The conflict of interest statement for N Kuster should read: “NK is director and board member of the non-profit IT’IS foundation that performs research in the field of exposure assessments for academia, governments, and industry. IT’IS has received funding for specific projects from most mobile phone manufacturers and many service providers, including the Mobile Manufacturers Forum, Motorola, Ericsson, Nokia, Samsung, Sony, GSM Association, ARIB Japan, Swisscom, Deutsche Telekom, and TDC Sunrise. NK is president of the board and shareholder of NF Technology Holding AG, which controls two companies, Schmid & Partner Engineering AG and ZMT Zurich Medtech AG, that develop near-field measurement instruments, simulation software, and medical test equipment.” This correction has been made to the online version as of June 25, 2015.
www.thelancet.com/oncology Vol 16 August 2015
Published Online June 25, 2015 http://dx.doi.org/10.1016/ S1470-2045(15)00119-9
e379
Correction to Lancet Oncol 2011; 12: 625 Baan R, Grosse Y, Lauby-Secretan B, et al, on behalf of the WHO International Agency for Research on Cancer Monograph Working Group. Carcinogenicity of radiofrequency electromagnetic fields. Lancet Oncol 2011; 12: 624–26—The conflict of interest statement for N Kuster should read: “NK is director and board member of the non-profit IT’IS foundation that performs research in the field of exposure assessments for academia, governments, and industry. IT’IS has received funding for specific projects from most mobile phone manufacturers and many service providers, including the Mobile Manufacturers Forum, Motorola, Ericsson, Nokia, Samsung, Sony, GSM Association, ARIB Japan, Swisscom, Deutsche Telekom, and TDC Sunrise. NK is president of the board and shareholder of NF Technology Holding AG, which controls two companies, Schmid & Partner Engineering AG and ZMT Zurich Medtech AG, that develop near-field measurement instruments, simulation software, and medical test equipment.” This correction has been made to the online version as of June 25, 2015.
www.thelancet.com/oncology Vol 16 August 2015
Published Online June 25, 2015 http://dx.doi.org/10.1016/ S1470-2045(15)00119-9
e379
